CHI3L1 as potential biomarkers of clinical conversion in CIS patients was firstly explored by Comabella et al. in two Spanish independent CIS cohorts and later confirmed in another study from a French cohort [48, 49]. The gene discussed is CHI3L1; the disease is in situ carcinoma.